The clinical outcomes of1 rituximab biosimilar CT-P10 (Truxima®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience

Kyoungmin Lee,Joo Young Ha,Ah Ra Jung,Yoon Sei Lee,Sang-wook Lee,Jin-Sook Ryu,Eun Jin Chae,Kyung Won Kim,Jooryung Huh,Chan-Sik Park,Dok Hyun Yoon,Cheolwon Suh

The clinical outcomes of1 rituximab biosimilar CT-P10 (Truxima®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience

2020

Kyoungmin Lee
Joo Young Ha
Ah Ra Jung
Yoon Sei Lee
Sang-wook Lee
Jin-Sook Ryu
Eun Jin Chae
Kyung Won Kim
Jooryung Huh
Chan-Sik Park
Dok Hyun Yoon
Cheolwon Suh

We evaluated real-world effectiveness and safety of CT-P10 (Truxima®) compared with originator rituximab in diffuse large B-cell lymphoma (DLBCL) treatment. Before and after the introduction of CT-...

Keywords:

Diffuse large B-cell lymphoma
Lymphoma
Biosimilar
Immunology
Medicine
CHOP
Rituximab Biosimilar CT-P10
Rituximab
Oncology
Internal medicine
first line
first line treatment
real world evidence

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations